

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-130) ADIMLECLEUCEL

PRONUNCIATION a" dim lek loo' sel

THERAPEUTIC CLAIM Treatment of cytomegalovirus viremia or disease

DESCRIPTION

Allogeneic Cytomegalovirus Cytotoxic T Lymphocytes (CMV-CTLs, ATA230) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens. CMV-CTLs have been generated from high resolution human leukocyte antigen (HLA)-typed CMV seropositive unrelated third-party T cells and are cryopreserved. CMV-CTLs exhibit HLA-restricted cytotoxic activity against CMV+ but not CMV- target cell and lack of alloreactivity. This therapy can be provided off-the-shelf when required by allogeneic hematopoietic cell transplant (alloHCT) or solid organ transplant (SOT) patients who have developed CMV viremia or disease.

TRADEMARK None as yet

SPONSOR Atara Biotherapeutics

CODE DESIGNATION CMV-CTL, ATA230

WHO NUMBER 10641

SCS